Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.
7 affiliations
- 1Department of Urology, the First Hospital of China Medical University, 155 North Nanjing Street, Shenyang, Liaoning, 110000, PR China.
- 2Institute of Urology, China Medical University, 155 North Nanjing Street, Shenyang, Liaoning, 110000, PR China.
- 3Department of Pathology, College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, 110112, PR China.
- 4China Medical University-The Queen's University of Belfast Joint College, China Medical University, Shenyang, Liaoning, 110112, PR China.
- 5Department of Pathology, The First Hospital of China Medical University, 155 North Nanjing Street, Shenyang, Liaoning, 110000, PR China.
- 6Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning, 110016, PR China.
- 7Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, PR China.
Abstract
Bladder, prostate, and renal cancers differ in their anatomical locations, tissue structures, and routes of clinical intervention. Conventional systemic treatments are often limited by nonspecific biodistribution, insufficient tumor accumulation, and toxicity. Localized nanomedicine delivery offers an alternative strategy by using organ-specific anatomical access to increase exposure at the tumor site and reduce systemic distribution. Its success depends on the compatibility of nanomedicine delivery systems with the physiological environment, anatomical characteristics, and procedural requirements of the organ. Here, we compare local nanomedicine strategies for these three cancers and discuss how anatomy can guide their design. We therefore define five design criteria for localized nanomedicines: retention, penetration, responsiveness, targeting, and synergy. For each criterion, describe relevant engineering approaches and applications in individual cancers. We also consider barriers to clinical use, including formulation reproducibility and compatibility with clinical workflows. An approach that combines anatomy, nanomedicine design, and delivery procedures may support their clinical translation for more precise diagnosis and treatment.
Related
- Multifunctional Nanomedicine for Precision Theranostics in Hepatic Fibrosis: From Rational Design to Clinical Translation.
- Artificial Intelligence-Enabled Nanomedicine in Precision Oncology: Diagnosis, Targeted Therapy, and Clinical Translation.
- Carbon Dots in Nanomedicine: Advanced Fabrication, Biomedical Applications, and Future Clinical Perspectives
- Nanomedicine in 2026: Illustrative Quantitative Analyses of EPR Heterogeneity, Clinical Trial Attrition, and Emerging Horizons for Active Nanotherapeutics
- Miniaturized biosensor platforms for early detection of neurodegenerative diseases and their potential for clinical translation
BibTeX
@article{zheng2026localized,
title = {{Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.}},
author = {Haoyuan Zheng and Yinan Yuan and Xianlu Zhang and Haiyang Li and Wanying Wang and Yiming Chen and Siru Nie and Jianbin Bi and Jin Sun and Xinxin Li},
journal = {Materials today. Bio},
year = {2026},
month = oct,
doi = {10.1016/j.mtbio.2026.103740},
url = {https://europepmc.org/article/MED/42898651},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.
AU - Haoyuan Zheng
AU - Yinan Yuan
AU - Xianlu Zhang
AU - Haiyang Li
AU - Wanying Wang
AU - Yiming Chen
AU - Siru Nie
AU - Jianbin Bi
AU - Jin Sun
AU - Xinxin Li
PY - 2026
DA - 2026/10/08
JO - Materials today. Bio
DO - 10.1016/j.mtbio.2026.103740
UR - https://europepmc.org/article/MED/42898651
AB - Bladder, prostate, and renal cancers differ in their anatomical locations, tissue structures, and routes of clinical intervention. Conventional systemic treatments are often limited by nonspecific biodistribution, insufficient tumor accumulation, and toxicity. Localized nanomedicine delivery offers an alternative strategy by using organ-specific anatomical access to increase exposure at the tumor site and reduce systemic distribution. Its success depends on the compatibility of nanomedicine delivery systems with the physiological environment, anatomical characteristics, and procedural requirements of the organ. Here, we compare local nanomedicine strategies for these three cancers and discuss how anatomy can guide their design. We therefore define five design criteria for localized nanomedicines: retention, penetration, responsiveness, targeting, and synergy. For each criterion, describe relevant engineering approaches and applications in individual cancers. We also consider barriers to clinical use, including formulation reproducibility and compatibility with clinical workflows. An approach that combines anatomy, nanomedicine design, and delivery procedures may support their clinical translation for more precise diagnosis and treatment.
SN - 2590-0064
ER -